Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome
- 1 August 2020
- journal article
- research article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (8) , 1078-1084
Abstract
Introduction Polycystic ovary syndrome (PCOS) is characterized by increased central fat mass (CFM), hyper-inflammation, and hemostatic alterations; the risk of cardiovascular disease may also be increased. Reduced fibrin lysability is a risk factor for cardiovascular disease. The present study assessed fibrin lysability in women with PCOS and controls of similar age and body mass index. Material and methods Ninety women with PCOS and 35 controls of comparable age and body mass index were included. Hemostatic markers (fibrin lysability, fibrinogen, coagulation factor XIII, plasminogen, plasminogen activator inhibitor 1 [PAI-1], plasmin inhibitor, thrombin activatable fibrinolysis inhibitor (TAFI), D-dimer), C-reactive protein (CRP), body mass index, waist-to-hip ratio, CFM determined by Dual-energy X-ray absorptiometry scan, and sex hormones (testosterone estradiol, and sex hormone binding globulin) were determined. Results TAFI and CRP were higher in women with PCOS, than controls. In women with PCOS, fibrin lysability correlated with CFM, waist-to-hip ratio, CRP, fibrinogen, and all hemostatic variables (P <= .004) except TAFI and D-dimer. CFM correlated with fibrinogen, CRP, coagulation factor XIII, waist-to-hip ratio, plasminogen, PAI-1, plasmin inhibitor, and TAFI (P < .02). In controls, fibrin lysability correlated with CFM, fibrinogen, coagulation factor XIII, and plasmin inhibitor (P <= .02). CFM correlated with PAI-1, plasmin inhibitor, coagulation factor XIII, fibrinogen, and CRP (P <= .05). Stepwise regression analysis revealed that fibrin lysability was associated with CFM, fibrinogen and CRP in women with PCOS (r(2) = .46, P <= .001), but only with CFM in controls (r(2) = .28, P < .001). Conclusions Fibrin lysability was comparable in women with PCOS and controls. Fibrin lysability was associated with CFM and hyper-inflammation in women with PCOS, but only with CFM in controls. These findings suggest that obese women with PCOS and augmented inflammation could have an increased risk of cardiovascular disease.Keywords
This publication has 28 references indexed in Scilit:
- Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysisHuman Reproduction Update, 2012
- Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generationAtherosclerosis, 2012
- Stimulated in vivo synthesis of plasminogen activator inhibitor-1 in human adipose tissueThrombosis and Haemostasis, 2012
- Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysisHuman Reproduction Update, 2011
- Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndromeGynecological Endocrinology, 2010
- Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndromeFertility and Sterility, 2009
- Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesityGynecological Endocrinology, 2006
- Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutismClinical Endocrinology, 2005
- Global Fibrinolytic Capacity Is Decreased in Polycystic Ovary Syndrome, Suggesting a Prothrombotic StateThe Journal of Clinical Endocrinology & Metabolism, 2002
- Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI‐1) activity in lean women with and without the polycystic ovary syndromeClinical Endocrinology, 1996